Patents by Inventor Zara Safarian

Zara Safarian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7141362
    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: November 28, 2006
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
  • Patent number: 7138245
    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: November 21, 2006
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
  • Publication number: 20050106640
    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.
    Type: Application
    Filed: October 14, 2004
    Publication date: May 19, 2005
    Applicant: Bio-Rad Laboratories, Inc., a corporation of the state of Delaware
    Inventors: Steven Binder, Jodi Goodrich, Zara Safarian
  • Publication number: 20050106632
    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.
    Type: Application
    Filed: October 13, 2004
    Publication date: May 19, 2005
    Applicant: Bio-Rad Laboratories, Inc.
    Inventors: Steven Binder, Jodi Goodrich, Zara Safarian
  • Patent number: 6660486
    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: December 9, 2003
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
  • Publication number: 20030113801
    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.
    Type: Application
    Filed: October 1, 2002
    Publication date: June 19, 2003
    Applicant: Bio-Rad Laboratories, Inc.
    Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
  • Publication number: 20030082828
    Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.
    Type: Application
    Filed: May 31, 2001
    Publication date: May 1, 2003
    Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
  • Patent number: 6171869
    Abstract: Protein-containing solutions requiring desalting and concentration are desalted and concentrated in a one step procedure. Ion exchange and ion retardation resins are used for desalting. A standard ultrafiltration device is modified to contain a mixed bed ion exchange resin and an ion retardation resin. The sample is introduced to the modified ultrafiltration unit and subjected to centrifugation. The centrifugal force drives low molecular weight constituents through the ultrafiltration membrane and draws liquid containing ion exchange products away from contact with the combined resins thereby driving the reaction to achieve a more complete desalting and concentration of the proteins in the sample solution. The proteins in the sample are thus concentrated and desalted simultaneously.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: January 9, 2001
    Assignee: Beckman Coulter, Inc.
    Inventors: Zara Safarian, Cynthia R. Blessum
  • Patent number: 5677422
    Abstract: A method for making a homogeneous succinylated polypeptide is disclosed. The method can be carried out by adding a succinyl-containing compound to a polypeptide solution, followed by raising the pH of the polypeptide solution to a pH of between about pH 10 to pH 12.5. The succinylation reaction between the succinyl-containing compound and free amino groups of the polypeptide is essentially complete upon raising the polypeptide solution pH to the alkaline pH.
    Type: Grant
    Filed: August 22, 1996
    Date of Patent: October 14, 1997
    Assignee: Beckman Instruments, Inc.
    Inventors: Zara Safarian, Hann-Ping Wang
  • Patent number: 5599433
    Abstract: A buffer and method useful for the analysis of glycoproteins by capillary zone electrophoresis. The buffer comprises water, a sugar complexing compound, a base compound for adjusting the pH, and a zwitterionic compound. An embodiment of the buffer comprises sodium borate as the complexing compound, sodium hydroxide as the base, and 3-cyclohexylamino-1-propanesulfonic acid as the zwitterionic compound. In the method, a selected glycoprotein is subjected to capillary zone electrophoresis. The proportion or the amount of the glycoprotein is determined by quantitative analysis of the resulting electropherogram.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: February 4, 1997
    Assignee: Beckman Instruments, Inc.
    Inventors: Nida Keo, Zara Safarian, Cheng-Ming Liu, Hann-Ping Wang
  • Patent number: 5431793
    Abstract: A method useful for determining the content of a first hemoglobin in a blood sample which also contains other forms of hemoglobin is based on capillary electrophoresis. In the method, a specific binding partner to the first form of hemoglobin is added to the sample, and the sample is then subjected to capillary electrophoresis. The method is particularly suited for the determination of the percentage of Hb A.sub.1c in a blood sample using anti-Hb A.sub.1c antibody.
    Type: Grant
    Filed: July 29, 1994
    Date of Patent: July 11, 1995
    Assignee: Beckman Instruments, Inc.
    Inventors: Hann-Ping Wang, Zara Safarian